AstraZeneca (LSE:AZN) has announced that the US Food and Drug Administration has accepted its new drug application for baxdrostat and granted it priority review. The therapy is intended for adults whose hypertension remains inadequately controlled despite existing treatment options.

The FDA has assigned a Prescription Drug User Fee Act (PDUFA) decision date in the second quarter of 2026.

AstraZeneca’s filing is supported by data from the Phase III BaxHTN study, which showed a statistically significant and clinically meaningful reduction in systolic blood pressure among participating patients. Baxdrostat is being developed to provide a new option for individuals whose high blood pressure remains difficult to manage using currently available medications.

This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.
Some portions of this content may have been generated or assisted by artificial intelligence (AI) tools and been reviewed for accuracy and quality by our editorial team.